29 results about "Macular degeneration" patented technology

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The present disclosure provides pharmaceutical compositions containing nucleic acid molecules encoding PEDF which are codon-optimized, as well as methods for increasing the level of PEDF in the treatment or prophylaxis of retinal degenerative diseases, such as age-related macular degeneration (AMD), or other neurodegenerative diseases.

This application provides a screening method and animal model related to intraocular diseases, such as age-related macular degeneration (AMD), for identifying candidate therapeutic agents for treating or preventing eye diseases, such as AMD. [Solution] The present application also provides compounds / compositions that can kill or inhibit the growth of microorganisms such as Bacillus megatherium. The present application further provides methods for treating infections caused by microorganisms such as Bacillus megatherium, and for treating or preventing diseases or disorders associated with such infections, such as AMD, using the compounds / compositions.

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“Bispecific RBP4 / TTR ligand”) is a chemical entity that binds to both TTR and RBP4 in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

Methods of using visual functions such as dark adaptation, low luminance visual acuity, low luminance deficit, contrast sensitivity and scotopic sensitivity as functional biomarkers for statin therapy in AMD. These biomarkers can be used, for example, to support clinical trials of statin therapy for AMD by identifying participants more likely to respond, by providing an early indication of response, or by serving as an endpoint; or to support treatment of AMD patients with statins by identifying patients more likely to respond, by providing an early indication of responders vs. non-responders, or by confirming a treatment benefit.

The application discloses a traditional Chinese medicine composition for treating senile macular retinal degeneration and a preparation method thereof. The traditional Chinese medicine composition is prepared from wolfberry fruit, chrysanthemum, milkvetch seed, dendrobium, panax notoginseng, raw safflower, and radix puerariae according to certain weight ratios. The traditional Chinese medicine composition is prepared into an oral preparation and has the effect of treating senile macular retinal degeneration.

The present disclosure relates to compounds and methods for preventing and treating macular degeneration, the methods comprising administering to the subject a compound of Formula (I). In some embodiments, the disclosure provides compounds and methods for treating cancer.

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration

This disclosure provides compositions and methods for the treatment of eye diseases associated with angiogenesis, in particular wet age-related macular degeneration.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.

The present disclosure provides systems and methods involving processing optical coherence tomography (OCT) images to predict characteristics of a treatment to be administered to effectively treat age-related macular degeneration. The processing can include pre-processing the images by planarizing and / or cropping the images, and processing the pre-processed images using a neural network. The neural network can include a deep convolutional neural network. The output of the neural network can indicate a predicted frequency and / or interval at which a treatment (e.g., an anti-vascular endothelial growth factor therapy) is to be administered in order to prevent leakage of vasculature in the eye.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

The present relates to VEGF traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, which bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.

The present invention relates to a stable, bioavailable, oral lipophilic nutrient composition comprising RR-zeaxanthin, curcuminoids, and / or lutein, along with nutraceutically acceptable excipients. In particular, the present invention provides a stable, bioavailable liquid oral composition comprising zeaxanthin isomers, curcuminoids, and / or lutein. The stable, bioavailable lipophilic nutrient composition of R, R-zeaxanthin, curcuminoids, and / or lutein is used for ophthalmic care, preferably for age-related eye diseases (AREDS), Age-related Macular degeneration (AMD), Visual dysfunction, Retinopathy, and other Eye diseases and disorders. The present invention further provides a process for preparing a nutraceutically stable and bioavailable lipophilic nutrient composition comprising zeaxanthin isomers, curcuminoids, and / or lutein.

The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of human immunoglobulin G (IgG) (in particular, a protein in which a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor and an Fc domain of human immunoglobulin G (IgG) are fused (e.g. Aflibercept)). The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused. The present invention can promote stabilization of physiological activity through a stable liquid formulation suitable for intravitreal injection of anti-VEGF-Fc fusion proteins including Aflibercept, and improve the therapeutic effect on various ophthalmic diseases caused by abnormal angiogenesis (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization, and wet age-related macular degeneration, etc.).

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and / or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

The application provides a traditional Chinese medicine composition for treating age-related macular degeneration, which is made of raw medicinal materials: Astragalus, Angelica sinensis, Ligustrum lucidum Ait, Scrophularia, Bupleurum, Radix Paeoniae Alba, Radix Rehmanniae, Pericarpium Citri Reticulatae, Coix, Fructus Aurantii, Forsythia. Clinical research shows that the traditional Chinese medicine composition can obviously improve the EDTRS letter number of the treatment group, and the total effective rates of Amsler table and visual field change after 6 months of treatment are 86.66% and 76.67% respectively.

The application provides use of an ELN gene or a plasmid or virus containing the same in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium. The application constructs an ELN overexpression vector, overexpresses the gene in a mouse eyeball, increases actin in a choroid layer and an RPE layer, and is beneficial to maintaining the structural morphology of the choroid and the RPE layer; and can maintain the tightness of a basal surface of the RPE layer and the integrity of the RPE structure, maintain the smoothness of a fiber structure of the choroid layer, and has no obvious influence on blood vessels and pigments of the choroid layer. It is illustrated that the ELN gene can be used for improving relaxation of the choroid and the RPE structure, remodeling the aging choroid and the RPE, and has application prospects in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium, such as a medicament for preventing and treating age-related macular degeneration.

Aptamers are single-stranded RNA or DNA molecules that bind to target molecules by forming complex three-dimensional structures. Their target molecules vary widely—including proteins, peptides, carbohydrates, lipids, small compounds, and metal ions—and because of their strong binding affinity and high specificity, aptamers have been put to practical use in fields such as therapeutics, diagnostics, and separation technologies. As pharmaceuticals, the world's first aptamer drug, Macugen®, was approved in the United States in 2004 as a treatment for neovascular age-related macular degeneration, and several other aptamers are now in clinical development. Research is also progressing on their use as tools in drug delivery systems (DDS), and the importance of aptamers in the pharmaceutical field is expected to continue growing. In this article, we provide an overview of aptamer acquisition methods and optimization strategies for therapeutic use, and introduce the latest developments in aptamer-based drugs currently in clinical trials.

Systems and methods disclosed herein relate to using a machine-learning model to process an input of a subject's eye and to predict a current or future visual acuity of the subject. The subject may have been diagnosed with age-related macular degeneration. The predicted current or future visual acuity may be used to (for example) facilitate diagnosing the subject (e.g., with a particular type of age-related macular degeneration), facilitate identifying a treatment strategy for the subject, and / or facilitate designing a clinical study.

This invention discloses the application of an LDHA inhibitor in the preparation of drugs for the prevention or treatment of dry age-related macular degeneration (AMD), belonging to the field of biomedical technology. The LDHA inhibitor is FX-11. This invention uses the LDHA inhibitor FX-11 as its core target, inhibiting excessive glycolysis by regulating the PPAR pathway, thereby suppressing inflammation, oxidative stress, and regulating energy metabolism balance, ultimately achieving the goal of regulating RPE glucose and lipid metabolism homeostasis. This novel treatment strategy provides a feasible pathway for metabolic intervention in dry AMD. Through multidimensional evidence from cellular level validation, animal model validation, and transcriptome mechanism analysis, the efficacy of FX-11 is systematically confirmed and its mechanism of action is explored, demonstrating strong scientific rigor and high reproducibility. This LDHA inhibitor FX-11 is not only applicable to dry AMD but also has the potential to be extended to the treatment of metabolic-related retinal diseases such as diabetic retinopathy and drug-induced RPE damage.

Disclosed is a tricyclic pyrimidinone compound of Formula (I) or a pharmaceutically acceptable salt thereof, which is a novel Lp-PLA2 inhibitor useful in treating neurodegeneration-related diseases such as Alzheimer's disease (AD), glaucoma and age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis.